The MLR Wall

Updated 2026-07-13 · markdown version

The MLR wall is the fixed regulatory chokepoint standing between every piece of pharmaceutical content and the world: MLR review committees in the US, certification by a final medical signatory in the UK, with FDA/OPDP and the PMCPA behind them. Nothing promotional ships around it. In the AI era the wall stops being mere process and becomes the terrain feature that decides the war — because it is precisely the step that automation cannot skip, rush, or impress.

Three properties make the wall decisive. It is provenance-blind to fluency: reviewers verify claims against sources; beautiful prose with an unverifiable number fails exactly as hard as clumsy prose. Its capacity is fixed and human: reviewer and signatory hours don't scale with drafting speed, so volume gains upstream become queue time at the wall — the verification asymmetry made architectural. Its incentives are asymmetric: an approver gets no reward for speed and full accountability for error (in the UK, personally), which makes the wall permanently conservative and permanently immune to "trust the model."

Strategies toward the wall define the two camps. One-button authoring treats the wall as someone else's problem: generate fast, let review sort it out — which in practice means parking generated content in longer queues. Co-creation tooling treats the wall as the design constraint: arrive substantiated, annotated, and pre-reviewed, and the wall becomes a doorway — one round instead of three.

The deepest read: the wall is not the industry's inefficiency. It is the industry's moat — the reason accountable human judgment cannot be priced out of medical communications, whatever the demo shows.